Concepedia

Melatonin and Metformin Failed to Modify the Effect of Dacarbazine in Melanoma

A.V. Novik Novik, Svetlana Anatolievna Protsenko, Irina Alexandrovna Baldueva, Lev Michailovich Berstein, Vladimir N. Anisimov, Irina Nikolaevna Zhuk, A.I. Semenova Semenova, Dilorom Khamidovna Latipova, Elena Tkachenko

The Oncologist · 2021 · 10 citations · 12 references

DOIFull text

Open access

Abstract

No benefit was found in either combination over DTIC monotherapy. Delayed responses in melatonin and metformin combination groups were registered. The increase of lymphocyte subpopulations responsible for antitumor immune response demonstrates the immune system's potential involvement in clinical activity.

References

12

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

, , +9

Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease.

Parris M. Kidd · PubMed · 2003 · 1.1K citations

, , +18

Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth

Monica Buzzai, Russell G. Jones, Ravi K. Amaravadi et al. · Cancer Research · 2007 · 915 citations · Full text

Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer

Enrique Rozengurt, James Sinnett‐Smith, Krisztina Kisfalvi · Clinical Cancer Research · 2010 · 247 citations · Full text

, , +17

A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma

Paolo Lissoni, Sandro Barni, Gabriele Tancini et al. · British Journal of Cancer · 1994 · 102 citations · Full text

, , +9